Press release
Lupus Nephritis Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes | Aurinia Pharmaceuticals, Otsuka Pharmaceutical, GlaxoSmithKline, AstraZeneca, Roche
DelveInsight's "Lupus Nephritis Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Lupus Nephritis, historical and forecasted epidemiology as well as the Lupus Nephritis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Lupus Nephritis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Lupus Nephritis Market Forecast
https://www.delveinsight.com/sample-request/lupus-nephritis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key facts of the Lupus Nephritis Market Report:
• The Lupus Nephritis market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
• In February 2025, the FDA approved Allogene Therapeutics' investigational new drug (IND) application for ALLO-329, an allogeneic CAR-T cell therapy. The Phase 1 RESOLUTION trial is expected to commence in mid-2025, targeting autoimmune diseases such as systemic lupus erythematosus (SLE), lupus nephritis, idiopathic inflammatory myopathies, and systemic sclerosis.
• In November 2024, Adicet Bio reported that the initial patient with lupus nephritis (LN) has received a dose in its Phase I clinical trial assessing ADI-001 for autoimmune disorders.
• In November 2024, Kyverna Therapeutics revealed plans to share updated clinical data from lupus nephritis (LN) patients treated with KYV-101 in its ongoing KYSA-1 and KYSA-3 Phase I/II trials, as well as through named patient treatments.
• In 2023, the United States contributed an estimated USD 1,500 million.
• GAZYVA/GAZYVARO (obinutuzumab) and SAPHNELO (anifrolumab) are among the promising emerging therapies poised to significantly impact and potentially reshape the lupus nephritis treatment landscape.
• By 2034, SAPHNELO (anifrolumab) is projected to lead the revenue among emerging lupus nephritis therapies in the United States, generating over USD 300 million.
• In the overall lupus nephritis market across the 7MM, the United States held the largest share-exceeding 80% in 2023-followed by Japan and Spain.
• In 2023, the United States held the largest portion of the market among the 7 Major Markets (7MM), amounting to 60%, with the UK following closely behind.
• In 2023, the market size for lupus nephritis in the EU4 countries and the UK was about USD 300 million.
• Pennesi and Benvenuto (2023) observed that lupus nephritis is more prevalent among children, occurring in 32-55% of cases, and tends to be more severe in this age group.
• According to DelveInsight, the total number of existing cases of systemic lupus erythematosus in the 7 Major Markets (7MM) was approximately 660,000 in 2023.
• Key Lupus Nephritis Companies: Hoffmann-La Roche, Genentech, Inc., Astrazeneca, Equillium, Novartis Pharmaceuticals, BeiGene, Boehringer Ingelheim, and others
• Key Lupus Nephritis Therapies: Obinutuzumab, Mycophenolate Mofetil, Anifrolumab, Itolizumab, Myfortic, Zanubrutinib, and others
Lupus Nephritis Overview
Lupus nephritis is a serious complication of systemic lupus erythematosus (SLE), an autoimmune disease. It specifically refers to inflammation of the kidneys caused by the immune system mistakenly attacking the kidney tissues.
Get a Free sample for the Lupus Nephritis Market Report:
https://www.delveinsight.com/report-store/lupus-nephritis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Lupus Nephritis Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Lupus Nephritis Epidemiology Segmentation:
The Lupus Nephritis market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Lupus Nephritis
• Prevalent Cases of Lupus Nephritis by severity
• Gender-specific Prevalence of Lupus Nephritis
• Diagnosed Cases of Episodic and Chronic Lupus Nephritis
Download the report to understand which factors are driving Lupus Nephritis epidemiology trends @ Lupus Nephritis Epidemiological Insights
https://www.delveinsight.com/sample-request/lupus-nephritis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Lupus Nephritis Market
The dynamics of the Lupus Nephritis market are anticipated to change in the coming years owing to the expected launch of emerging therapies such as Obinutuzumab, Myfortic, and others during the forecasted period 2020-2034.
Lupus Nephritis Therapies and Key Companies
• LUPKYNIS (voclosporin): Aurinia Pharmaceuticals/Otsuka Pharmaceutical
• BENLYSTA (belimumab): GlaxoSmithKline
• SAPHNELO (anifrolumab): AstraZeneca
• GAZYVA/GAZYVARO (obinutuzumab): Roche
• Obinutuzumab: Hoffmann-La Roche
• Mycophenolate Mofetil: Genentech, Inc.
• Anifrolumab: Astrazeneca
• Itolizumab: Equillium
• Myfortic: Novartis Pharmaceuticals
• Zanubrutinib: BeiGene
To know more about Lupus Nephritis treatment, visit @ Lupus Nephritis Medications
https://www.delveinsight.com/sample-request/lupus-nephritis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Lupus Nephritis Market Drivers
• Increase in research activities
• Increasing disease prevalence
• Surge in a number of clinical studies
Lupus Nephritis Market Barriers
• High Lupus Nephritis Treatment costs
• Need for novel Lupus Nephritis therapeutics
• Surge in a number of clinical studies
• Need for targeted treatment regimen
Scope of the Lupus Nephritis Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Lupus Nephritis Companies: Hoffmann-La Roche, Genentech, Inc., Astrazeneca, Equillium, Novartis Pharmaceuticals, BeiGene, Boehringer Ingelheim, and others
• Key Lupus Nephritis Therapies: Obinutuzumab, Mycophenolate Mofetil, Anifrolumab, Itolizumab, Myfortic, Zanubrutinib, and others
• Lupus Nephritis Therapeutic Assessment: Lupus Nephritis current marketed and Lupus Nephritis emerging therapies
• Lupus Nephritis Market Dynamics: Lupus Nephritis market drivers and Lupus Nephritis market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Lupus Nephritis Unmet Needs, KOL's views, Analyst's views, Lupus Nephritis Market Access and Reimbursement
Discover more about therapies set to grab major Lupus Nephritis market share @ Lupus Nephritis Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/lupus-nephritis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Table of Contents
1. Lupus Nephritis Market Report Introduction
2. Executive Summary for Lupus Nephritis
3. SWOT analysis of Lupus Nephritis
4. Lupus Nephritis Patient Share (%) Overview at a Glance
5. Lupus Nephritis Market Overview at a Glance
6. Lupus Nephritis Disease Background and Overview
7. Lupus Nephritis Epidemiology and Patient Population
8. Country-Specific Patient Population of Lupus Nephritis
9. Lupus Nephritis Current Treatment and Medical Practices
10. Lupus Nephritis Unmet Needs
11. Lupus Nephritis Emerging Therapies
12. Lupus Nephritis Market Outlook
13. Country-Wise Lupus Nephritis Market Analysis (2020-2034)
14. Lupus Nephritis Market Access and Reimbursement of Therapies
15. Lupus Nephritis Market Drivers
16. Lupus Nephritis Market Barriers
17. Lupus Nephritis Appendix
18. Lupus Nephritis Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Related Reports:
Lupus Nephritis Pipeline https://www.delveinsight.com/report-store/lupus-nephritis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
"Lupus Nephritis Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Lupus Nephritis market. A detailed picture of the Lupus Nephritis pipeline landscape is provided, which includes the disease overview and Lupus Nephritis treatment guidelines.
Lupus Nephritis Epidemiology https://www.delveinsight.com/report-store/lupus-nephritis-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Lupus Nephritis Epidemiology Forecast to 2034' report delivers an in-depth understanding of the disease, historical and forecasted Lupus Nephritis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Latest Reports by DelveInsight
• Optical Coherence Tomography Devices Market: https://www.delveinsight.com/report-store/optical-coherence-tomography-oct-devices-market
• Prediabetes Market: https://www.delveinsight.com/report-store/prediabetes-market
• Scoliosis Market: https://www.delveinsight.com/report-store/scoliosis-market
• Psoriasis Market: https://www.delveinsight.com/report-store/psoriasis-market
• Tendinitis Market: https://www.delveinsight.com/report-store/tendonitis-market
• Vascular Closure Devices Market: https://www.delveinsight.com/report-store/vascular-closure-devices-market
• Apheresis Market: https://www.delveinsight.com/report-store/apheresis-market
• Hydrocephalus Market: https://www.delveinsight.com/report-store/hydrocephalus-market
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Lupus Nephritis Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes | Aurinia Pharmaceuticals, Otsuka Pharmaceutical, GlaxoSmithKline, AstraZeneca, Roche here
News-ID: 4084045 • Views: …
More Releases from DelveInsight Business Research
Spinocerebellar Ataxias Pipeline 2025: Comprehensive Clinical Trials and Therapi …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Spinocerebellar Ataxias pipeline constitutes 8+ key companies continuously working towards developing 10+ Spinocerebellar Ataxias treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Spinocerebellar Ataxias Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Spinocerebellar Ataxias Market.
The Spinocerebellar…
Presbyopia Market to Evolve Rapidly Over the Next Decade by 2034, DelveInsight O …
The Presbyopia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Presbyopia pipeline products will significantly revolutionize the Presbyopia market dynamics.
DelveInsight's "Presbyopia Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Presbyopia, historical and forecasted epidemiology as well as the Presbyopia market trends in the United States, EU5 (Germany, Spain, Italy, France,…
Idiopathic Pulmonary Fibrosis Market Insights Highlight Expanding Outlook Till 2 …
DelveInsight's "Idiopathic Pulmonary Fibrosis Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Idiopathic Pulmonary Fibrosis, historical and forecasted epidemiology as well as the Idiopathic Pulmonary Fibrosis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
The latest healthcare forecast report provides an in-depth analysis of Idiopathic Pulmonary Fibrosis, offering comprehensive insights into the Idiopathic Pulmonary Fibrosis revenue trends,…
Myocardial Infarction Market Positioned for Accelerated Development Through 2034 …
DelveInsight's "Myocardial Infarction Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Myocardial Infarction, historical and forecasted epidemiology as well as the Myocardial Infarction market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Myocardial Infarction market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Myocardial Infarction Market Forecast
https://www.delveinsight.com/sample-request/myocardial-infarction-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the…
More Releases for Lupus
Prominent Cutaneous Lupus Erythematosus Market Trend for 2025: Advancements In C …
What combination of drivers is leading to accelerated growth in the cutaneous lupus erythematosus market?
The rising prevalence of skin infections is expected to drive the growth of the cutaneous lupus erythematosus (CLE) market. Skin infections are caused by microorganisms that invade the skin, triggering immune responses that can worsen symptoms in individuals with CLE. For example, the UK saw a 33.7% increase in MRSA cases caused by skin and soft…
Primary Catalyst Driving Lupus Therapeutics Market Evolution in 2025: Rising Res …
"What Is the Future Outlook for the Lupus Therapeutics Market's Size and Growth Rate?
The market size for lupus therapeutics has seen substantial growth in the past few years. It is projected to expand from $2.74 billion in 2024 to $2.99 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 8.9%. The historic growth of this market can be associated with a rise in cases of lupus, increased funding…
Cutaneous Lupus Erythematosus (CLE) Market
Market Overview:
The Global Cutaneous Lupus Erythematosus (CLE) Market is forecasted to achieve a High CAGR during the period 2023-2030. CLE encompasses a spectrum of dermatological symptoms that may precede or accompany systemic lupus erythematosus (SLE), an autoimmune condition impacting multiple organs. Timely diagnosis and treatment of CLE can prevent the onset of severe systemic symptoms.
Market Dynamics:
Drivers:
Rise in Clinical Studies: Technological advancements leading to faster and accurate diagnosis have spurred additional…
Lupus Nephritis Treatment Market 2030
Global Lupus Nephritis Treatment market is expected to be worth roughly USD 8,048 million by 2030, growing at a CAGR of 7.3% during the forthcoming period of 2022-2030, according to Ameco Research
Lupus nephritis is one of the most rapidly spreading diseases over the globe. The increasing frequency of lupus nephritis and consumer awareness has fuelled the worldwide lupus nephritis treatment market. Another crucial factor driving the pace of growth of…
Lupus Erythematosus Market -API Insights, 2017
Summary
Orbis Research Present “Lupus Erythematosus-API Insights, 2017”
Description
The active pharmaceutical ingredients worldwide market is in continuous development from the recent years. There is expected to be a major impact on the global API industry, with the large number of blockbuster drugs going off patent in the coming years. It is going to affect the revenue of the API market as generic drugs occupy the market.
India and China produce a large percentage…
Global Systemic Lupus Erythematosus and Lupus Nephritis Market to Display 10.6% …
"The Report PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Global Drug Forecast and Market Analysis to 2025 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz"
MarketResearchReports.biz has announced the addition of a new report, titled “PharmaPoint: Systemic Lupus Erythematosus And Lupus Nephritis - Global Drug Forecast And Market Analysis To 2025,” to its expanding repository of research reports. The market…
